FDA staff opposed both forms. PCAC favored both.
The official record contains limited human evidence and substantial nonclinical literature, but the exact form, dosage form, route, duration and safety questions remain unresolved.
FDA staff recommended against both forms; PCAC voted favorably on both form-level questions.
Unlike several other subjects in the hearing, BPC-157 was not a zero-human-data record. FDA reviewed a small randomized ulcerative-colitis study and nonclinical gastrointestinal findings.
FDA briefing pp. 26–32The evidence did not establish the safety or effectiveness of both chemical forms across the nominated dosage forms and routes, and it did not resolve long-term treatment.
FDA briefing pp. 39–46The committee outcome belongs beside the evidence record—not on top of it. A favorable advisory vote describes the panel’s recommendation on compounding eligibility; it does not erase FDA’s characterization, route-match or human-evidence concerns.
These are attributed testimony arguments, not PeptideBase endorsements. Each one is paired with the most relevant FDA answer and an explicit assessment of what the evidence can—and cannot—carry.
Only named speaker moments reconciled against a word-timestamped machine transcript of the official recording appear here. The method is two-pass transcript reconciliation: both passes read that same transcript, so this is not audio review and not independent primary-source confirmation. Where the two passes disagreed about who was speaking, the moment was withheld rather than published. Statements remain attributed arguments unless the underlying evidence was independently established from a named source outside the hearing record, and each moment carries its own disclosed limitations.
Board-certified urologist, private practice, Indianapolis
Verify credentialsTatem argued that individualised 503A compounding is a distinct legal pathway from drug approval, and that access was removed in 2023 without an explanation he could trace to an authority. He then summarised a 2025 systematic review and proposed mechanisms (FBXO22 stabilisation, VEGFR2 engagement) as evidence that the substance is not uncharacterised in the literature.
President and Executive Director, Center for Science in the Public Interest; former FDA Associate Commissioner
Verify credentialsLurie said CSPI opposed adding all seven substances, for three reasons: that listing would be inconsistent with FDA’s own compounding standards, that compounded products pose distinct consumer risks, and that listing would remove incentives to develop products through the standard drug-approval pathway.
The testimony identifies a real distinction between research reagents and material intended for human use. The hearing record did not independently establish that a compliant supply chain had already solved the exact identity, impurity and finished-product questions for either nominated form.
FDA concluded that BPC-157 free base and BPC-157 acetate are not well characterized from a physical and chemical characterization perspective.
FDA Day 1 presentation · 03:14:38The critique supports tighter sourcing and release controls. It does not, by itself, characterize the exact nominated substances or a finished compounded preparation.
The favorable majority appears to have given weight to the distinction between bulks-list eligibility and drug approval, plus the possibility of a more accountable supply chain. FDA’s review asked whether the exact forms were adequately characterized and supported across the nominated dosage forms and routes (oral capsule, subcutaneous injection, nasal spray, rectal suppository, transdermal cream); it concluded they were not.
Editorial inference from the hearing record—not an attributed rationale for every voterThese are recurring propositions in the wider peptide discussion, not attributed speaker quotations.
FDA discussed a randomized, double-blind, placebo-controlled study in 53 people with mild-to-moderate ulcerative colitis; 46 completed two weeks of BPC-157 or placebo enema treatment.
The evidence was available as a meeting abstract with limited methodological detail. The studied enema was not the same dosage form as the nominated rectal suppository, and it did not address the nominated oral, subcutaneous, nasal or transdermal products.
FDA described gastrointestinal and wound-related effects in rodent models, including colonic-fistula and gastrointestinal-injury experiments.
FDA said dose-response relationships were not established, molecular targets were unidentified and mechanisms remained poorly understood. Nonclinical findings do not establish effectiveness in people with ulcerative colitis.
“Absent” means FDA said it did not identify that evidence within this evaluation. It is not a universal claim that no evidence exists anywhere.
| Evidence question | Status | FDA-record summary | Locator |
|---|---|---|---|
| Human clinical evidence | limited | FDA-record summaryA 53-subject randomized enema study was described in a meeting abstract; detail and duration were limited. | LocatorBriefing pp. 26–28, 53 |
| Nonclinical evidence | indirect | FDA-record summaryRodent gastrointestinal and injury models were identified, but translation to the nominated compounded products is unresolved. | LocatorBriefing pp. 29–32 |
| Exact-form match | unresolved | FDA-record summaryFDA reported that the clinical articles “submitted by the nominators and those identified by FDA do not always clearly identify BPC-157 as a free base or salt,” and referred to the substance generally as BPC-157 throughout. The record does not establish which form the evidence concerns. | LocatorBriefing pp. 7–12, 29 |
| Nominated-route match | limited | FDA-record summaryRectal enema data were identified; the nominated dosage forms included oral, SC, nasal, rectal suppository and transdermal products. | LocatorBriefing pp. 7–8, 26–28 |
| Evaluated-use match | limited | FDA-record summaryThe short ulcerative-colitis study matched the evaluated condition, but did not resolve long-term effectiveness. | LocatorBriefing pp. 25–28 |
| Product characterization | not well characterized | FDA-record summaryFDA concluded that BPC-157 free base and BPC-157 acetate are not well characterized from the physical and chemical characterization perspective, citing naming conventions that do not follow established chemical nomenclature standards, and data on certain critical quality attributes for identity, purity and quality in the proposed dosage forms that were lacking or inadequate. | LocatorBriefing pp. 17, 21 |
| Human safety | limited | FDA-record summaryShort rectal exposures were described with limited monitoring; FDA found long-term safety information insufficient. | LocatorBriefing pp. 39–45 |
| Historical compounding use | limited | FDA-record summaryFDA found the available information too limited to understand historical compounding use. | LocatorBriefing pp. 21–25 |
Qualitative evidence map · no numerical score · scoped to FDA’s July 2026 evaluation
A useful dossier should show the reader what evidence could materially strengthen or weaken the current read.
Controlled human trials identifying the exact chemical form, dosage form and route
Long-term safety data appropriate to a chronic ulcerative-colitis treatment
Validated identity, impurity, aggregation and finished-product specifications
The central technical issue is identity: FDA treated the seven-amino-acid TB-500 fragment as distinct from full-length thymosin beta-4 and found no direct human TB-500 evidence.
Open dossierDay 1KPV’s official-record case is primarily mechanistic and nonclinical. FDA said it found no human administration or exposure data by any route.
Open dossierFree newsletter
The Peptide Research Digest
Weekly analysis on providers, sourcing and compounds — from the team behind PeptideBase.